glp-1 brain fog Did you know GLP-1 medications may support more than just weight How might GLP-1 drugs like

arthralgia incidence in trials is generally similar to placebo Rapid weight loss from GLP-1 treatment may alter biomechanical loading on joints, causing temporary adjustment-related discomfort Patients prescribed GLP-1 medications often have type 2 diabetes or obesity, conditions independently associated with increased osteoarthritis rates Seek medical advice for severe, worsening, or persistent joint pain, or if accompanied by swelling, redness, warmth, or systemic symptoms Report suspected medication side effects through the MHRA Yellow Card scheme to support ongoing safety monitoring Table of Contents Understanding GLP-1 Medications and Their Common Side Effects GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), most commonly cause gastrointestinal side effects such as nausea, vomiting, and diarrhoea

Cost has been just one of the barriers

Compounded Brand name medications may be a good fit if: You have insurance coverage You prefer FDA-approved medications that have undergone extensive testing You're comfortable with the higher cost for brand name products Compounded medications may be a good fit if: You don't have insurance coverage and need a more affordable option You've discussed the options with your healthcare provider, clinician, or medical team Your provider offers compounded medications and uses a licensed compounding pharmacy Your doctor or clinician determines it's appropriate for your situation Always consult with your healthcare provider, clinician, or medical team to determine which option is best for your individual needs and circumstances

Acute pancreatitis In January 2026, the UK MHRA has instructed manufacturers to update the product information for all GLP-1 and dual GIP/GLP-1 receptor agonists to highlight the potential risk of severe acute pancreatitis associated with these drugs, including rare reports of necrotizing and fatal pancreatitis [13]

Published in the Lancet Psychiatry, the research also examined data on new diagnoses of anxiety and depression

The median treatment duration for participants was 15.9 months